Characteristics | Low-risk arm (group C) | High-risk arm | |
---|---|---|---|
NAC prophylaxis cohort (group A) | Control cohort (group B) | ||
Number of patients | 105 | 80 | 40 |
Median age (range), years | 31 (15–55) | 31 (15–53) | 30 (15–48) |
Male gender, N (%) | 61 (58.1) | 41 (51.3) | 27 (67.5) |
Diagnosis, N (%) | |||
 AML | 57 (54.3) | 41 (51.2) | 22 (55.0) |
  refined disease risk index | |||
   Low (favorable cytogenetics, any CR) | 3 (5.3) | 6 (14.6) | 0 |
   Intermediate (intermediate cytogenetics, any)CR) | 30 (52.6) | 21 (51.2) | 12 (54.5) |
   High (adverse cytogenetics, any CR) | 24 (42.1) | 14 (34.1) | 10 (45.5) |
  Remission status | |||
   First CR (CR1) | 51 (90.5) | 37 (90.2) | 22 (100) |
   Second CR (CR2) | 6 (9.5) | 4 (9.8) | 0 |
 ALL | 48 (45.7) | 39 (48.8) | 18 (45.0) |
  refined disease risk index | |||
   Intermediate (CR1) | 47 (97.9) | 37 (94.9) | 17 (94.4) |
    High (CR2) | 1 (2.1) | 2 (5.1) | 1(5.6) |
 Philadelphia positive | 15 (31.3) | 11 (28.2) | 6 (33.3) |
Measurable residual disease before transplant, N (%) | |||
 Negative | 65 (61.9) | 53 (66.2) | 23 (57.5) |
 Positive | 40 (38.1) | 27 (33.8) | 17 (42.5) |
Median time from diagnosis to HSCT(range), months | 5 (3–24) | 5 (2–42) | 5 (3–12) |
Median donor age(range), years | 40 (10–64) | 45 (10–66) | 37 (8–61) |
HLA-A, B, DR mismatched grafts, N (%) | |||
 1 | 5 (4.8) | 2 (2.4) | 1 (2.5) |
 2 | 21 (20.0) | 15 (18.8) | 5 (12.5) |
 3 | 79 (75.2) | 63 (78.8) | 34 (85.0) |
Donor-recipient gender matched, N (%) | |||
 Male-male | 43 (41.0) | 31 (38.8) | 20 (50.0) |
 Male-female | 29 (27.6) | 30 (37.5) | 11 (27.5) |
 Female-male | 18 (17.1) | 10 (12.5) | 7 (17.5) |
 Female-female | 15 (14.3) | 9 (11.2) | 2 (5.0) |
Donor-recipient relationship, N (%) | |||
 Father-child | 37 (35.2) | 42 (52.5) | 18 (45.0) |
 Mother-child | 11 (10.5) | 4 (5.0) | 2 (5.0) |
 Sibling-sibling | 23 (21.9) | 12 (15.0) | 7 (17.5) |
 Child-parent | 30 (28.6) | 19 (23.8) | 13 (32.5) |
 Collateral relatives | 4 (3.8) | 3 (3.8) | 0 |
ABO matched grafts, N (%) | |||
 Matched | 50 (47.6) | 43 (53.8) | 23 (57.5) |
 Major mismatch | 22 (21.0) | 17 (21.3) | 5 (12.5) |
 Minor mismatch | 25 (23.8) | 15 (18.8) | 10 (25.0) |
 Bi-directional mismatch | 8 (7.6) | 5 (6.3) | 2 (5.0) |
Median chemo cycles pre-HSCT (range) | 3 (2–9) | 3 (2–12) | 3 (2–14) |
≥2 Induction cycles to achieve CR, N (%) | 18 (17.1) | 16 (20.0) | 9 (22.5) |
Median CD34+ cells, 106/kg (range) | 2.86 (0.77–14.10) | 3.15 (0.49–9.42) | 3.31 (0.92–7.45) |